Cardiol Therapeutics Inc (CRDL) News

CRDL grabbed some July19 2.50 calls at a nickel, lotto play, chart looking better…

Good!

Higher lows...still bullish

I like!

>$4 likely

Back to $3?

There's volume...looks like run will continue

Yeah...we need to keep plenty of rainy day cash in the jar lol

Tough week, no doubt

My portfolio is in a depression at the moment...may have to eat dirt ala mode for dinner tonight

There will not be one until after they submit which wu probably be around $1-$1.50 area

RGDL too high too fast...will wait on pullback

Will look at it...watch CDRL go lower now that I text you...I bet I jinxed it lol

Nice. $RDGL about to go up big time!

Morning...there are signs this is stablizing...both my CRDL and WMT calls are green this morning

Im finding more and more playing options
are the way to go if careful

No doubt

...all depends which way the wind blows

It looks excessive but wouldn’t be surprised to see the $1-1.50 range after it run up with $2 being the area it settles in before its first leg up following this downturn

Im thinking they're diluting because they need money for phase 3 trial...otherwise I dont know why the huge sell off

1.50 could be bottom but 1.75 more likely

$1 bid here if my $1.50’s get filled

Nice

I got em...bought 10

Agreed

Nah...it only allows .05 increments...bidding .15...dont want to bid .20...if doesnt fill will let it go and buy something else...tomorrow is a stock mkt holiday and its summer so a weak mkt is expected

Gm- u get filled?

GM... bidding 6/19 2.50 calls @.15

I’m adding about 500-1k a day for the next couple of weeks

I added a little today...already have plenty...we will do quite well when thos recovers...surprised this crashed

The wrecking ball hit my portflio this morning lol...I'm holding...will wait out this dip

Added this morning and adding more now

Hey we're way oversold here...please add

Yeah they have a low float...so quite volatile

Jump all over this...treat the dip as your friend

CRDL, the old buy-the-rumor, sell-the-news…

Biotechs get big swings, doesn’t mean CRDL won’t work out longer term…

What is happening, why the deep plunge?

$CRDL Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

https://finance.yahoo.com/news/cardiol-therapeutics-announces-positive-topline-115800368.html

CRDL new 52 week high

Welcome to the Cardiol Therapeutics hotel...our guests sleep well here

Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotech drug developer focused on developing their novel ultrapure cannabidiol formulation, CardiolRx™, for rare inflammatory heart diseases, specifically recurrent pericarditis and acute myocarditis.

Pericarditis is characterized as inflammation of the pericardium, layers of tissue that surround the heart, that affects about 165,000 people in the U.S. annually and has no first-line FDA-approved treatment. Among those treated for acute pericarditis, 15% to 30% may experience recurrent pericarditis.

Currently, anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment in cases of chronic or recurrent pericarditis. If the patient with pericarditis disease does not respond to anti-inflammatory medications, corticosteroids such as prednisone are prescribed.

More recently, Kiniksa Pharmaceuticals’ ARCALYST® (rilonacept) became the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence in adults and children 12 years and older.

ARCALYST is a weekly subcutaneous injection, whereas CardiolRx™ is an oral drug taken twice daily which is a major advantage as the idea of weekly injections could not be as appealing to patients.

Cardiol Therapeutics’ (NASDAQ:CRDL) pre-clinical models showed that by inhibiting activation of the NLRP3 inflammasome pathway, cannabidiol may help resolve the symptoms of pericarditis.

This approach has already demonstrated incredible potential, as the company was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol Therapeutics followed this major achievement with completing enrollment in its Phase 2, open-label MAvERIC-Pilot study investigating the tolerance, safety, and effect of CardiolRx™ in patients with recurrent pericarditis. The primary endpoint of the trial is the change in patient-reported pericarditis pain using an 11-point numeric rating scale (NRS) from baseline to week 8 with topline results expected in early June.

Not only that, Cardiol Therapeutics recently presented its concurrent Phase II ARCHER trial design at the annual congress of the Heart Failure Association of the European Society of Cardiology. This demonstrated the high level of interest from the cardiology community in novel approaches to treat acute myocarditis, for which there are currently no therapies approved by European and US regulatory authorities.

The ARCHER trial is expected to enroll 100 patients at pre-eminent cardiovascular research centers in the United States, Canada, France, Brazil, and Israel. Patient recruitment has been accelerating due in large part to the growing global awareness of myocarditis, and ARCHER has already exceeded 85% of target enrollment.

Cardiol Therapeutics (NASDAQ:CRDL) expects that results from the ARCHER trial will assist in furthering its understanding of the therapeutic potential of CardiolRx™ and will complement the more advanced MAvERIC-Pilot Phase II study in patients with recurrent pericarditis.

Just to put the opportunity here in context, Future Market Insights expects that the worldwide pericarditis treatment market is likely to be worth $ 6 billion by 2032. ARCALYST’s sales further reaffirm this considering that the drug’s 2023 net revenue grew 90% year-over-year to $233.1 million.

Several analysts have maintained their positive outlook on the company and have high hopes that the June data will further prove CardiolRx™ efficacy in treating recurrent pericarditis. In fact, Joe Gantoss of Chimera Research Group notes, “I won’t be surprised to see the price breaking out the 3-year high at $4.96 if the recurrent-pericarditis data show a clear success and open the path to move to the next stage with Phase-3 trial,” while analysts at H.C Wainwright & Co. issued a $9 price target for the stock.

https://www.theglobeandmail.com/investing/markets/markets-news/TheNewswire.com/26745778/surging-biotech-ma-reaffirms-massive-opportunity-in-rare-disease-drug-development/

First in first out

Are you picking your nose on this one? You aren't posting...Am I the only one cleaning up here?

Ripping!

Will recover next week

Dip and rip!!!!$$$$

$4 easy then 5

EPIC CALL!!!$$$

Buy and hold

Rock on...